Baxalta

Ticker: BXLT

Initial purchase: 7/1/2015 (BAX spinoff)

Cost basis: $36.02

Current Portfolio Status: Other

Dividend Reinvestment: N

Dividends paid quarterly in Jan, Apr, Jul, Oct

Shares held on account at Motif

Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, including hemophilia A, hemophilia B, acquired hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency. The company’s principal products include ADVATE, a recombinant factor VIII therapy for the treatment of children and adults with hemophilia A; FEIBA, an inhibitor management therapy; GAMMAGARD LIQUID, a liquid formulation of the antibody-replacement therapy for the treatment of immune deficiencies and certain neurological disorders; and HYQVIA, an immune globulin with a recombinant human hyaluronidase for the treatment of PID in adults. It is also developing products in the areas of hematology, oncology, immunology, and biosimilars. The company has collaboration agreements with National Center for Advancing Translational Sciences, Coherus BioSciences, Inc., Merrimack Pharmaceuticals, Inc., and Momenta Pharmaceuticals, Inc., as well as licensing agreement with CTI BioPharma Corp. Baxalta Incorporated was incorporated in 2014 and is based in Bannockburn, Illinois. Baxalta, Inc. was spun off from Baxter International, Inc. July 1, 2015.

Reason for holding: Pending acquisition by Shire

Advertisements

One thought on “Baxalta

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s